来凯医药-B 港股通 空最新增减持 (2026-07-09) 官网 ( 02105.hk) | -12.98 | 2.52 | 0% | 上市时间2023-06-29股价7.37港币涨跌幅3.80%成交金额952.86万港币换手率0.28%市值33.12亿港币H股市值33.12亿港币总股本4.49亿H股本4.49亿每手股数500上市至今年化投资收益率-21.08%港股通持仓占H股比例6.56% (2.13亿港币2026-07-08) 累计做空占H股比例2.49% (8,726.25万港币2026-07-03) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 120.34 | 市净率 | 4.39 | 股息率 | 0.38% | 恒生:医疗保健业药品及生物科技生物技术 |
| 备注 (2): | 双击编辑备注 |
来凯医药-B(02105) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 鄒國強 | Independent Non Executive Director - A/F | 2023-06-16 | -- | |
| 2 | LI Min | Independent Non Executive Director | 2023-06-16 | -- | |
| 3 | YIN Xu Dong | Independent Non Executive Director | 2023-06-16 | -- | |
| 4 | GU Xiang Ju Justin | Executive Director | 2022-05-09 | -- | |
| 5 | 孫淵 | Non Executive Director | 2022-04-28 | -- | |
| 6 | 吉冬梅 | Non Executive Director | 2022-04-28 | 2023-09-29 | |
| 7 | 王國瑋 | Non Executive Director | 2019-07-01 | -- | |
| 8 | XIE Ling | Executive Director | 2018-05-11 | -- | |
| 9 | LU Xiang Yang Chris | Executive Director | Chairman | 2016-07-29 | -- |